{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:39:11Z","timestamp":1787240351913,"version":"build-2736575974"},"reference-count":47,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Innovation and Technology and the National Research, Development and Innovation Office, Hungary","award":["NVKP_16-1-2016-0005"],"award-info":[{"award-number":["NVKP_16-1-2016-0005"]}]},{"name":"Ministry of Innovation and Technology and the National Research, Development and Innovation Office, Hungary","award":["TKP2020-NKA-19"],"award-info":[{"award-number":["TKP2020-NKA-19"]}]},{"name":"Hungarian Society for Hematology and Transfusiology","award":["NVKP_16-1-2016-0005"],"award-info":[{"award-number":["NVKP_16-1-2016-0005"]}]},{"name":"Hungarian Society for Hematology and Transfusiology","award":["TKP2020-NKA-19"],"award-info":[{"award-number":["TKP2020-NKA-19"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Belantamab mafodotin (belamaf) is an afucosylated monoclonal antibody conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF) that targets B cell maturation antigen (BCMA) on the surface of malignant plasma cells. Belamaf can eliminate myeloma cells (MMs) through several mechanisms. On the one hand, in addition to inhibiting BCMA-receptor signaling and cell survival, intracellularly released MMAF disrupts tubulin polymerization and causes cell cycle arrest. On the other hand, belamaf induces effector cell-mediated tumor cell lysis via antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. In our in vitro co-culture model, the consequences of the first mentioned mechanism can be investigated: belamaf binds to BCMA, reduces the proliferation and survival of MMs, and then enters the lysosomes of malignant cells, where MMAF is released. The MMAF payload causes a cell cycle arrest at the DNA damage checkpoint between the G2 and M phases, resulting in caspase-3-dependent apoptosis. Here, we show that primary MMs isolated from different patients can vary widely in terms of BCMA expression level, and inadequate expression is associated with extremely high resistance to belamaf according to our cytotoxicity assay. We also reveal that primary MMs respond to increasing concentrations of belamaf by enhancing the incorporation of mitochondria from autologous bone marrow stromal cells (BM-MSCs), and as a consequence, MMs become more resistant to belamaf in this way, which is similar to other medications we have analyzed previously in this regard, such as proteasome inhibitor carfilzomib or the BCL-2 inhibitor venetoclax. The remarkable resistance against belamaf observed in the case of certain primary myeloma cell cultures is a cause for concern and points towards the use of combination therapies to overcome the risk of antigen escape.<\/jats:p>","DOI":"10.3390\/ijms24065303","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T02:30:33Z","timestamp":1678415433000},"page":"5303","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Effect of Belantamab Mafodotin on Primary Myeloma\u2013Stroma Co-Cultures: Asymmetrical Mitochondrial Transfer between Myeloma Cells and Autologous Bone Marrow Stromal Cells"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1458-8549","authenticated-orcid":false,"given":"Zsolt","family":"Matula","sequence":"first","affiliation":[{"name":"Laboratory for Experimental Cell Therapy, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, 1097 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"Uher","sequence":"additional","affiliation":[{"name":"Laboratory for Experimental Cell Therapy, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, 1097 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"V\u00e1lyi-Nagy","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, 1097 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2204-7398","authenticated-orcid":false,"given":"G\u00e1bor","family":"Mikala","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, 1097 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"Pawlyn","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","article-title":"How I treat myeloma with new agents","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ajh.26080","article-title":"New regimens and directions in the management of newly diagnosed multiple myeloma","volume":"96","author":"Bal","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ajh.26379","article-title":"Chimeric antigen receptor T-cells, bispecific antibodies, and antibody- drug conjugates for multiple myeloma: An update","volume":"97","author":"Lakshman","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1177\/10781552211073517","article-title":"The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma","volume":"28","author":"Davis","year":"2022","journal-title":"J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab Mafodotin: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2040620720979813","DOI":"10.1177\/2040620720979813","article-title":"The role of belantamab mafodotin for patients with relapsed and\/or refractory multiple myeloma","volume":"11","author":"Becnel","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): A dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2217\/fon-2020-1269","article-title":"Belantamab mafodotin in combination with novel agents in relapsed\/refractory multiple myeloma: DREAMM-5 study design","volume":"17","author":"Nooka","year":"2021","journal-title":"Future Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood-2021-152224","article-title":"Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14","volume":"138","author":"Hultcrantz","year":"2021","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1182\/blood-2019-129893","article-title":"Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom\/Dex) in Participants with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"134","author":"Weisel","year":"2019","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-139332","article-title":"DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib\/Dexamethasone (BorDex) in Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Popat","year":"2020","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-139181","article-title":"DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Rifkin","year":"2020","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-139785","article-title":"DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Trudel","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood-2021-153315","article-title":"DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma","volume":"138","author":"Usmani","year":"2021","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1182\/blood-2021-152662","article-title":"DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"138","author":"Callander","year":"2021","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo","volume":"20","author":"Alavi","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1517\/14712598.6.11.1161","article-title":"Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies","volume":"6","author":"Satoh","year":"2006","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.2147\/DDDT.S267404","article-title":"Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety","volume":"15","author":"Offidani","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Matula, Z., Mikala, G., Lukacsi, S., Matko, J., Kovacs, T., Monostori, E., Uher, F., and Valyi-Nagy, I. (2021). Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells. Cancers, 13.","DOI":"10.3390\/cancers13143461"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/17474086.2017.1285694","article-title":"Triplet combinations in relapsed\/refractory myeloma: Update on recent phase 3 trials","volume":"10","author":"Boudreault","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-021-01109-y","article-title":"Emerging therapies for relapsed\/refractory multiple myeloma: CAR-T and beyond","volume":"14","author":"Su","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"20406207221100659","DOI":"10.1177\/20406207221100659","article-title":"Toxicity management strategies for next-generation novel therapeutics in multiple myeloma","volume":"13","author":"Steinbach","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12967-022-03285-y","article-title":"B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages","volume":"20","author":"Nobari","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/curroncol28010063","article-title":"Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects","volume":"28","author":"Lassiter","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-139182","article-title":"Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Richardson","year":"2020","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40265-022-01697-0","article-title":"BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy","volume":"82","author":"Paul","year":"2022","journal-title":"Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Nishida, H. (2021). Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. Cancers, 13.","DOI":"10.3390\/cancers13112712"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"25764","DOI":"10.18632\/oncotarget.25359","article-title":"Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma","volume":"9","author":"Bu","year":"2018","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood-2010-01-264424","article-title":"APRIL promotes cell-cycle progression in primary multiple myeloma cells: Influence of D-type cyclin group and translocation status","volume":"117","author":"Quinn","year":"2011","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ymthe.2018.06.012","article-title":"CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin\u2019s Lymphoma and Multiple Myeloma","volume":"26","author":"Bluhm","year":"2018","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41408-020-0337-y","article-title":"B-cell maturation antigen expression across hematologic cancers: A systematic literature review","volume":"10","author":"Dogan","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1189\/jlb.4VMR0915-395R","article-title":"Linked in: Immunologic membrane nanotube networks","volume":"100","author":"Zaccard","year":"2016","journal-title":"J. Leukoc. Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5303\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:51:43Z","timestamp":1760122303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24065303"],"URL":"https:\/\/doi.org\/10.3390\/ijms24065303","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]}}}